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PREDICTABILITY AND COSTS ASSOCIATED WITH GOOD AND POOR MO-
BILIZERS USING A COMBINATION OF VP-16 AND G-CSF FOR PERIPH-
ERAL BLOOD STEM CELL (PBSC) MOBILIZATION AND COLLECTION
Wood, W.A., Whitley, J.S., Moore, D.T., Sharf, A., Irons, R., Rao, K.V.,
Serody, J.S., Gabriel, D.A., Coghill, J.M., Shea, T.C. University of North
Carolina at Chapel Hill, NC
Introduction: The combination of chemotherapy and G-CSF for
stem cell mobilization prior to autologous stem cell transplantation
(ASCT) provides additional cytoreduction and generally higher cell
yields than cytokine alone.We have investigated the use of mid-dose
VP-16 plus G-CSF as a regimen with little toxicity that can take ad-
vantage of these properties. Here, we report our experience with this
regimen for pts with multiple myeloma and lymphoma, focusing on
poor mobilizers.
Methods: Between May 2004 and June 2009, 152 pts with MM
and 136 pts with lymphoma (98 NHL, 38 HD) underwent
ASCT following the use of VP-16 (375 mg/m2 on D#1 and
D#2) and G-CSF (5mcg/kg twice daily from D#3 through the final
day of collection) for mobilization. 14 pts also received one dose of
Rituximab (375 mg/m2) on D#1. Collection was initiated when the
peripheral blood CD34 count was .7/ul. National averages and
UNC-specific costs were used to calculate total costs associated
with mobilization. The costs of second and third mobilizations
were not included. Logistic regression was used to analyze the re-
lationship between pre-mobilization variables and stem cell yields.
Poor mobilizers were defined as pts failing to collect 5  106 cells
in one or two days.
Results: Of 152 pts with MM, 2 (1%) were poor mobilizers,
compared with 54 of 136 (40%) pts with lymphoma
(p\0.001). 9 required .1 mobilization for yields less than 2 
106. Average total costs for lymphoma pts were $14488 (good
mobilizers) vs $26082 (poor mobilizers), with etoposide account-
ing for $2640 in each. There were differences in G-CSF use
($5390 vs $8216), pheresis procedures ($1857 vs $5635), and
product processing, storage and infusion ($1649 vs $4382) be-
tween the two groups. Transfusions and treatment for fevers
were more frequent in poor mobilizers ($294.95 vs $1467.40/
pt) and may also have reflected marrow reserve in this group.
The best predictor for poor mobilization in lymphoma pts was
a pre-collection CD34 peripheral blood count\26/
ul(p\0.0001). This yielded a sensitivity of 89% and specificity
of 86% for predicting poor mobilizers.
Conclusion:ThoughVP-16 andG-CSF is an effective mobilization
regimen for nearly all pts with MM, a significant proportion of lym-
phoma pts are poor mobilizers and experience higher costs and com-
plication rates. The peripheral blood CD34 count on the day of
apheresis appears to be the best predictor of good or poor mobiliza-
tion when using this regimen in lymphoma pts.210
RACIAL DIFFERENCES IN OUTCOME AFTER AUTOLOGOUS HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: INFLU-
ENCE OF TIME TO REFERRAL TO TRANSPLANT CENTER
Manos, J.A., Costa, L.J., Schaub, C., Stuart, R.K. Medical University of
South Carolina, Charleston, SC
Background: Autologous hematopoietic stem cell transplantation
(AHSCT) is considered a key component of the management of
newly diagnosed, transplant eligible, multiple myeloma (MM) pa-
tients. Survival after diagnosis of multiple myeloma is inferior in Af-
rican-American (AA) patients when compared to Caucasian patients.
Whether this difference persists in patients treated with AHSCT is
unknown and conflicting results have arisen from different series.
We analyzed the differences in outcome between Caucasian (C)
and non-Caucasian (NC-predominantly AA) patients undergoing
AHSCT for MM at our institution inquiring if differences in time
to referral to the transplant center would translate into differences
in outcome.
Methods: Retrospective analysis of the Medical University of South
Carolina (MUSC)MM transplant database with particular attentionto time from diagnosis to transplant (surrogate for time to referral)
and survival after transplantation.
Results: Between 1999 and 2009, 102 patients underwent a first
AHSCT for MM at MUSC. Sixty two patients (61%) were C and
40 (39%) NC (38 were AA). Median age at the time of diagnosis
was 58 (39-70) for C and 56 (34-69) for NC (p5 n.s.). Fifty four
(53%) were female. There was no difference between C and NC in
hemoglobin, calcium, creatinine or B2 microglobulin prior to
AHSCT. Nine three (91%) patients received conditioning chemo-
therapy with Melphalan 200 mg/m2. Day 100 mortality was 4%
(4.8% for C vs. 2.5% for NC, P5 n.s.). Median interval from diag-
nosis to transplant, a surrogate of access to care, was 10 months
(range 3-57) for C and 10 months (range 5-42) for NC (p5 n.s.).
There was no difference between racial groups in overall survival
from the time of diagnosis (median 59.3 months for C vs. 53.3
months for NC, P5 n.s) or from the time of first AHSCT (median
51.8 months for C vs 36.5 months for NC, P5 n.s.).
Conclusion: In a setting where caucasian and non-caucasian pa-
tients have similar access to AHSCT, no race-associated discrepancy
in outcome was identified. Inferior outcome for AA patients with
MM reported in prior series may have resulted exclusively from dif-
ferences in access to treatments, including AHSCT.211
ALLOGENEIC REDUCED-INTENSITY STEM CELL TRANSPLANTATION
WITH FLUDARABINE AND MELPHALAN FOR REFRACTORY OR RELAPSED
FOLLICULAR LYMPHOMA
Ono, Y., Mori, T., Kato, J., Aisa, Y., Okamoto, S. Keio University School
of Medicine, Tokyo, Japan
Some reports have demonstrated the efficacy of allogeneic stem
cell transplantation (SCT) for refractory or relapsed follicular
lymphoma. To reduce the transplant-related mortality, reduced-
intensity stem cell transplantation has recently been used. We
here present the results of a retrospective analysis of the safety
and efficacy of allogeneic RIST for refractory or relapsed follicu-
lar lymphoma.
Patients andMethods:Twenty-two patients with relapsed and re-
fractory follicular lymphoma underwent RIST at Keio University
Hospital between July 2002 and January 2009 were retrospectively
evaluated. The median age at the time of transplant was 49.5years
(range: 34-62). Stem cell sources and donor type were bone mar-
row or peripheral blood stem cells from human leukocyte anti-
gen(HLA)-identical sibling (n5 6), bone marrow from HLA-
serologically matched unrelated donor (n5 14), or cord blood
stem cells from unrelated donor (n5 2). The conditioning regi-
men consisted of fludarabine (125 mg/m2) and melphalan
(140 mg/m2). Four or eight Gy of total body irradiation was added
for cord blood transplantation (n5 2). For the prophylaxis of
graft-versus-host disease (GVHD), cyclosporin A (CSA) with
short-term methotrexate (MTX) was given for SCT from a sibling
donor, and tacrolimus with short-term MTX was given for SCT
from an unrelated donor including cord blood transplantation
(CBT).
Results: All patients achieved neutrophil engraftment. The me-
dian follow-up period of the 18 patients who were alive at the
date of analysis was 54 months (range: 7- 85 months). Causes of
deaths were bacterial infection in 2 patients, and severe GVHD
in 2 patients. The 5-year overall survival was 81% (95% CI:
65.1%-97.8%), and progression free survival is 71.5% (95% CI
52.1%-90.9%). Although disease relapse was observed in 2 pa-
tients who had undergone CBT, complete remission was reach-
ieved solely by the discontinuation of tacrolimus. Surviving
patients are all in good condition, and had an ECOG performance
status of 0 or 1.
Conclusion:These results strongly suggest that RIST could be a cu-
rative treatment for refractory or relapsed follicular lymphoma, and
provide an excellent survival. Because of a low risk of disease relapse
and a possibility of inducing graft-versus-lymphoma effect, more in-
tensive immunosuppressive therapy should be considered in order to
reduce GVHD-related mortality.
